Targeted Therapy at the End of Life for Patients with Lung Cancer
- 1 August 2010
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Palliative Medicine
- Vol. 13 (8), 945-948
- https://doi.org/10.1089/jpm.2010.0084
Abstract
The use of chemotherapy at the end of life is increasing. We characterized the use of targeted therapies in relation to the end of life in non–small cell lung cancer (NSCLC) patients who died in our institution. The frequency of systemic anticancer therapy usage at the end of life was consistent with that reported in other recent studies. The use of targeted therapies, especially epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), was strikingly more common than that of conventional chemotherapy. Targeted therapy was frequently initiated within the last 3 months of life. Targeted agents were also used in sequence, in combination, and in investigational protocols. We conclude that targeted agents, in particular EGFR TKIs, are now the drugs of choice in the systemic treatment of NSCLC at the end of life.Keywords
This publication has 12 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for ChemotherapyJournal of Clinical Oncology, 2009
- Evidence for Disease Control with Erlotinib after Gefitinib Failure in Typical Gefitinib-Sensitive Asian Patients with Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysisPsycho‐Oncology, 2007
- Chemotherapy Given Near the End of Life by Community Oncologists for Advanced Non-Small Cell Lung CancerThe Oncologist, 2006
- Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL StudyJournal of Thoracic Oncology, 2006
- Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease EntityJournal of Clinical Oncology, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- EGFR Mutation Is Specific for Terminal Respiratory Unit Type AdenocarcinomaThe American Journal of Surgical Pathology, 2005
- Trends in the Aggressiveness of Cancer Care Near the End of LifeJournal of Clinical Oncology, 2004